FOLH1 and prostate cancer: Prostate-specific membrane antigen (PSMA) ligand positron emission tomography (PET) combined with computed tomography (CT) radically improved prostate cancer (PC) imaging thanks to its superior sensitivity compared to CT and bone scintigraphy [1].